Dr Reddy’s has launched generic Paricalcitol injection in US

September 20, 2016

Dr Reddy’s Laboratories has launched generic Paricalcitol injection which is used in the treatment associated with chronic kidney disease in the US.

It has said in a BSE filing that the firm has launched the injection USP in the strengths of 2 mcg, 5 mcg and 10 mcg.

It further said that the company’s product is generic version of AbbVie Inc’s Zemplar injections.

According to it, the injection is first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration.

Read EquityPandit’s Nifty Pharma Outlook for this week

MARKETS

Bharti Hexacom Shares Surged 5% on Tower Sale Halted

Ali WaghbakriwalaApril 11, 2025April 11, 2025

April 11, 2025April 11, 2025

Shares of Bharti Hexacom Ltd were trading in the green and 5% higher on Friday 11 April after the company temporarily stopped its contract to sell 3,400 towers to Indus Towers for Rs 1,134 crore.

This comes after the Government of India intervened through Telecommunications Consultants India Limited (TCIL), which owns a 15% share in the company.

In an exchange filing, Bharti Hexacom indicated that the existing proposal has been put on hold and that a new exercise will be conducted after consultation with TCIL.

In February, Indus Towers purchased 16,100 telecom towers from Bharti Airtel and Bharti Hexacom for Rs 3,308.7 crore in cash. It was hoped that the agreement will be completed by 31 March.

Indus announced on Wednesday that it has “executed the transaction” to purchase the passive infrastructure business venture of Bharti Airtel.

The deal required Bharti Hexacom to sell 3,400 towers and Airtel to sell 12,700 towers to Indus. According to Indus, the planned acquisition will increase the tower company’s market share and assist it to achieve its expansion ambitions while also aligning with its principal business.

At 2:25 pm, the shares of Bharti Hexacom were trading 4.78% higher at Rs 1,501 on NSE.

Got Bharti Hexacom Ltd Questions? The Analyst is Ready.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!

MARKETS

Metal Stocks Surge 7% on 90-Day Pause Note

Ali WaghbakriwalaApril 11, 2025April 11, 2025

April 11, 2025April 11, 2025

After US President Donald Trump announced a 90-day stop to the global trade war, metal shares became the largest sectoral gainer today as worries over the conflict subsided. The index also gained momentum after Tata Steel announced plans to restructure its operations in the Netherlands.

The Nifty Metal index grew by 4.44%, the most since 5 March 2025, when it had grown by over 4%. Lloyds Metals and Energy, the index’s biggest gainer, rose 6.81% to hit an intraday high of Rs 1,230 a share on the NSE.

Tata Steel was in second, jumping 5.9% to a high of Rs 134.7 due to its objectives for change in the Netherlands.

Tata Steel Nederland plans to remove around 1,600 jobs in management and support functions as part of a large-scale transformation strategy aimed at enhancing efficiency and preparing for a green steel future.

“This transformation is a building block towards the future,” said T. V. Narendran, CEO and MD of Tata Steel and Chairman of the Supervisory Board of Tata Steel Nederland. “We want to ensure Tata Steel Nederland regains its position as one of the most efficient steelmakers in Europe while taking definitive steps toward sustainability.”

According to the company, these adjustments will improve its operating and financial profile, allowing it to make future investments and maintain its competitiveness in a market that is changing quickly.

Tata Steel will change its operations in the Netherlands and eliminate 1,600 jobs.

The metal majors on the index, which rose up to 4%, included Hindalco Industries, JSW Steel, and the Steel Authority of India.

Tata Steel and Hindalco have significant exposure to US exports. This is why their equities were among the top gainers today following the tariff postponement.

Prior to Trump’s 90-day delay, metal stocks had fallen on expectations of a slowdown in the United States and a rippling effect in other economies, which might reduce demand for metals. The hefty tariffs imposed on around 60 countries raised concerns about product dumping into countries such as India, depressing native participants in the sector.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

MARKETS

BHEL Shares Gained 2% on Inking MoU with Nuovo Pignone International

Ali WaghbakriwalaApril 11, 2025April 11, 2025

April 11, 2025April 11, 2025

The share price of Bharat Heavy Electricals (BHEL) increased by 2% on 11 April after the company signed a long-term (10-year) Memorandum of Understanding (MOU) with Nuovo Pignone International s.r.l. to address compressor revamp opportunities in India’s fertiliser sectors.

BHEL would be the principal (lead) bidder to the specified clients for addressing the compressor train overhaul business possibilities in India’s fertiliser sector, and Nuovo Pignone International will be nominated as a vendor to BHEL under the subject MoU with a specific scope of work.

On 3 April, Rajasthan Part I Power Transmission, a 100% subsidiary of Adani Energy Solutions (AESL), signed a contract with Hitachi Energy India to design and build 6,000 MW, ±800 kV, bi-pole, and bi-directional high-voltage direct current (HVDC) terminals to transport renewable energy from Bhadla, Rajasthan, to the industrial and transportation hub in Fatehpur, Uttar Pradesh.

On 28 March, a Letter of Intent (LoI) for a project worth Rs 11,800 crore was delivered to the corporation by the Chhattisgarh State Power Generation Corporation Limited (CSPGCL).

The share hit a 52-week high of Rs 335.40 on 9 July 2024, and a 52-week low of Rs 176.00 on 3 March 2025.

At 12:30 pm, the shares of BHEL were trading 1.74% higher at Rs 215.50 on NSE.

Wondering About Bharat Heavy Electronics Ltd? The Analyst Has Answers.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!

MARKETS

Cipla Shares Rallied 5% on Securing Approval from USFDA

Ali WaghbakriwalaApril 11, 2025April 11, 2025

April 11, 2025April 11, 2025

The share price of Cipla Ltd rallied 5% on 11 April after the company announced securing approval from the US Food and Drug Administration (USFDA) for its cancer drug.

In its regulatory filing, the company said that the USFDA approved the Abbreviated New Drug Application (ANDA) for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (also called “Protein-bound Paclitaxel”) on 10 April 2025.

In an exchange filing, Cipla, said, “We hereby notify that the company has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (‘Protein-bound Paclitaxel’) on 10 April, 2025.”

Nonetheless, the product is expected to debut in the United States in the first half of fiscal year 2025-2026.

Paclitaxel is prescribed for the treatment of metastatic breast cancer, metastatic pancreatic adenocarcinoma, and locally advanced or metastatic non-small cell lung cancer (NSCLC). Furthermore, Cipla’s Protein-bound Paclitaxel is an AB-rated generic medication that is equal to Bristol Myers Squibb’s Abraxane® for Injectable Suspension 100 mg/vial.

Cipla is a worldwide pharmaceutical firm with over 80 years of experience dedicated to making quality healthcare available to everyone.

With operations in more than 80 nations, the company is renowned for its wide range of pharmaceutical products, which include more than 1,500 products in several therapeutic areas.

The company is a respiratory care leader, has produced unique drug-device combinations, and has had a significant global impact with its pioneering work in HIV/AIDS treatment, particularly by decreasing the cost and boosting access to triple antiretrovirals in Africa.

Cipla is still committed to accessibility and cost, particularly in developing regions like Africa and India where it is well-established.

At 11:38 am, the shares of Cipla were trading 2.61% higher at Rs 1,452.60 on NSE.

Curious About Cipla Ltd? Ask the Analyst.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!

MARKETS

Stocks in Focus: BHEL, Coromandel International, Biocon, and Others

Ali WaghbakriwalaApril 11, 2025April 11, 2025

April 11, 2025April 11, 2025

The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading higher by 476 points at 22,956 indicating that the domestic benchmark indices are likely to make a positive start on Friday.

On Wednesday, 9 April, Domestic benchmark indices S&P BSE Sensex slumped by 380 points or 0.51% and settled at 73,847, while the Nifty50 traded 0.61% lower by 137 points, settling at 22,399.

Here are some stocks that are likely to remain in focus on 11 April.

BHEL: The company has announced the signing of a Memorandum of Understanding (MoU) with Nuovo Pignone International S.r.l. to address compressor revamp opportunities in India’s fertilizer sector.

Coromandel International: Coromandel has deepened its long-standing collaboration with Saudi-based mining giant Ma’aden, one of the leading global producers of phosphate fertilizers by signing a Memorandum of Understanding (MoU). This strategic alliance is aimed at securing a steady and timely supply of Di-Ammonium Phosphate (DAP) and NP/NPK fertilizers for farmers across India.

Biocon: Biocon Biologics, the subsidiary of the company, has announced securing approval from the US Food and Drug Administration (USFDA) Jobevne, which is used to treat various types of cancer.

NBCC: The company has announced selling 1,185 residential units at Aspire Dream Valley, Phase III, Greater Noida (West), UP via an e-auction, achieving a total sale of Rs 1,504.69 crore.

Tata Consultancy Services: In its quarterly earnings for January-March, the company reported a 1.7% year-on-year decline in net profit to Rs 12,224 crore due to delays in decision-making, rising uncertainty, and project ramp-downs.

JSW Energy: The company has announced that it had successfully acquired a 4.7 GW renewable energy platform from O2 Power Pooling Pte. Ltd. for an enterprise value of roughly Rs 12,468 crore through its wholly owned subsidiary JSW Neo Energy.

Aurobindo Pharma: The subsidiary of the company, CuraTeQ Biologics, has announced the completion of a Phase-1 pharmacokinetic (PK) and pharmacodynamic (PD) study that targets the critical protein in the lifecycle of osteoclasts—cells that break down bone.

Infosys: The company has announced a strategic partnership with AIB to deliver application development and maintenance services, AI-power tooling, and agile practices.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!

EquityPandit

Get Daily Prediction & Stocks Tips On Your Mobile

EquityPandit